Clinical Trials at Karmanos Cancer Institute at McLaren Greater Lansing
As of August 2026, 21 paid clinical trials are recruiting at Karmanos Cancer Institute at McLaren Greater Lansing, located at Karmanos Cancer Institute at McLaren Greater Lansing, 3520 Forest Rd, Lansing, MI 48910, phone (517) 975-9500 in Lansing, Michigan. Active studies at this site cover conditions such as Stage IV Lung Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 and Breast Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
21 clinical trials at Karmanos Cancer Institute at McLaren Greater Lansing
·Clear filters·Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
A Study of the TheraBionic P1 Device in Breast Cancer
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
Ask Questions About Clinical Trials
Common conditions studied in Lansing
- Stage IV Lung Cancer AJCC v8 (7 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (5 active studies)
- Breast Cancer (5 active studies)
- Stage IVB Prostate Cancer AJCC v8 (5 active studies)
- Recurrent Lung Non-Small Cell Carcinoma (4 active studies)
- Stage IIIB Lung Cancer AJCC v8 (4 active studies)
Leading research sponsors in Lansing
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- Alliance for Clinical Trials in Oncology
- NRG Oncology
- Barbara Ann Karmanos Cancer Institute
Frequently asked questions
How many paid clinical trials are currently recruiting in Lansing?
There are approximately 134 recruiting clinical trials in Lansing, Michigan listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Lansing pay participants?
Most recruiting trials in Lansing compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Lansing?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Lansing?
The most common conditions under active study in Lansing include Stage IV Lung Cancer AJCC v8 (7), Anatomic Stage II Breast Cancer AJCC v8 (5), Breast Cancer (5), Stage IVB Prostate Cancer AJCC v8 (5), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Lansing?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Lansing on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Lansing?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Lansing?
Recruiting research sites in Lansing include University of Michigan Health - Sparrow Lansing, Karmanos Cancer Institute at McLaren Greater Lansing, Sparrow Clinical Research Institute, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Lansing right now?
The largest active categories in Lansing are Cancer & tumors (80), Cardiovascular (13), Neurology & pain (3). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Karmanos Cancer Institute at McLaren Greater Lansing?
Karmanos Cancer Institute at McLaren Greater Lansing is located at Karmanos Cancer Institute at McLaren Greater Lansing, 3520 Forest Rd, Lansing, MI 48910. Use the Google Maps link in the intro above to get directions.
How do I contact Karmanos Cancer Institute at McLaren Greater Lansing?
You can reach Karmanos Cancer Institute at McLaren Greater Lansing by phone at (517) 975-9500. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.